Welcome to our dedicated page for Insmed SEC filings (Ticker: INSM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Insmed Incorporated (INSM) brings together the company’s official disclosures to U.S. regulators, offering investors a structured view of its financial condition, material events, and risk factors. As a global biopharmaceutical company focused on serious and rare diseases, Insmed uses filings such as Forms 10-K, 10-Q, and 8-K to report on the performance of its commercial products, the status of its clinical programs, and significant corporate developments.
In periodic reports like the Form 10-K and Form 10-Q, readers can expect detailed discussions of product revenues from therapies such as ARIKAYCE and BRINSUPRI, research and development spending across respiratory, immunology & inflammation, and gene therapy programs, and commentary on liquidity, capital resources, and risks associated with drug development and commercialization. These filings also describe the company’s manufacturing arrangements, intellectual property portfolio, and broader business strategy within pharmaceutical preparation manufacturing.
Current reports on Form 8-K provide timely updates on specific events, including FDA and European Commission approvals of BRINSUPRI, topline clinical results from studies like the Phase 2b BiRCh trial in chronic rhinosinusitis without nasal polyps, and acquisitions such as INS1148, an investigational monoclonal antibody for respiratory and inflammatory indications. Earnings-related 8-Ks furnish quarterly financial results, while other items may address regulatory milestones, changes in development plans, or key conference presentations.
Stock Titan’s platform enhances these documents with AI-powered summaries that explain complex sections of lengthy filings in accessible language. Users can quickly understand how new data or regulatory decisions may affect Insmed’s product portfolio, pipeline, and financial profile, while still having direct access to the underlying EDGAR-sourced documents for deeper analysis.
Insmed Incorporated reported positive topline results from its Phase 3b ENCORE study of ARIKAYCE in patients with newly diagnosed MAC lung infection not previously treated with antibiotics. ARIKAYCE plus multidrug therapy improved Respiratory Symptom Score at Month 13 by 17.77 points versus 14.66 with placebo, a 3.11‑point advantage (p=0.0299), and achieved culture conversion by Month 6 in 87.8% of patients versus 57.0% with placebo. By Month 15, a significantly greater proportion of ARIKAYCE patients maintained durable culture conversion, and overall study completion exceeded 90% in both arms, with a safety profile consistent with known risks such as dysphonia, cough and bronchospasm. These results fulfill the U.S. FDA post‑marketing requirement, and Insmed plans a supplemental NDA in the second half of 2026 to seek U.S. label expansion and conversion of ARIKAYCE’s existing refractory indication to traditional approval, as well as a parallel submission to Japan’s PMDA.
INSMED Inc Chair and CEO William Lewis exercised stock options and sold shares in a planned transaction. On 2026-03-19, he exercised options for 10,699 shares of common stock at exercise prices of $30.46 and $17.16 per share, converting them into common shares.
That same day, he sold 10,699 shares of common stock in open-market trades at weighted average prices ranging from about $141.80 to $144.72, under a pre-arranged Rule 10b5-1 trading plan adopted on September 4, 2025. After these transactions, he directly holds 301,185 shares, plus 233,924 shares held indirectly through the Katie Procter Dynasty Trust.
William Lewis filed a Form 144 reporting proposed sales of issuer common stock. The filing lists multiple Stock Plan Activity entries with proposed dispositions dated 03/19/2026 and earlier trade dates. Examples shown include proposed sales of 10,699 shares on 03/05/2026 and 10,699 shares on 02/19/2026. The filing lists repeated transactions under the same reporting address and identifies the market as NASDAQ.
INSM filed a Form 144 disclosing sales of Common stock by William Lewis. The filing lists multiple reported sale entries under Stock Plan Activity and a section titled Securities Sold During The Past 3 Months, with dated line items ranging from 12/18/2025 to 03/05/2026.
INSMED Inc Chair and CEO William Lewis reported multiple transactions in company stock. On 2026-03-05, he exercised stock options for 6,259 and 4,440 shares of common stock through derivative conversions. He then sold a total of 10,699 common shares in open-market transactions at weighted average prices noted in the filing, effected under a Rule 10b5-1 trading plan adopted on September 4, 2025. After these trades, he held 301,185 common shares directly and 233,924 common shares indirectly through the Katie Procter Dynasty Trust as of that date.
INSMED Inc director Melvin Sharoky, MD reported a bona fide gift of common stock. On March 3, 2026, an entity associated with him transferred 100 shares of common stock as a gift transfer at a reported price of $0.0000 per share, reducing his directly held shares to 242,776.
He also reported several indirect holdings: 6,847 shares held by his spouse, 5,000 shares held by Padonia, LLC, where he is the managing member, and custodial UTMA/FL accounts holding 819, 5,423, 5,007, and 3,724 shares for named family beneficiaries.
Insmed Inc director Melvin Sharoky reported several bona fide gifts of common stock dated February 25, 2026. He gifted 1,072 shares from his direct holdings and 243 shares to each of four UTMA custodial accounts for family members. After these gifts, he continued to hold 242,876 shares directly, while indirect holdings included shares in custodial UTMA accounts, 5,000 shares held through Padonia, LLC, and 6,847 shares held by his spouse.
Insmed Inc’s Chief Legal Officer, Michael Alexander Smith, reported option exercises and share sales in company stock. On February 24, 2026, he exercised a stock option for 20,248 shares, converting a derivative security into common stock at a reported price of $17.07 per share.
On the same date, he sold a total of 24,774 shares of common stock in open-market transactions at weighted average prices of $153.93, $155.06, and $156.53 per share, under a Rule 10b5-1 trading plan adopted on November 7, 2025. After these transactions, he directly owned 51,871 common shares of Insmed.
INSMED Inc director David R. Brennan reported a bona fide gift of 6,000 shares of Common Stock. The gift was made on February 23, 2026 at a reported price of $0.00 per share, indicating it was a non-cash, charitable or personal transfer rather than a sale.
After this disposition, Brennan directly holds 60,933 shares of INSMED Common Stock. In addition, an indirect holding of 60,000 shares is reported as being held by a spouse revocable trust, reflecting shares associated with, but not directly owned by, the director.
INSM filed a Form 144 disclosing recent resale notices and issuer stock plan activity. The filing lists multiple issuer plan issuances on 01/04/2026, 01/05/2026, 01/06/2026, 02/01/2026, and 02/24/2026 with amounts of 1,554, 874, 1,312, 786, and 20,248 shares respectively.
The filing also shows sales by Michael Smith on 01/06/2026 (1,396 shares), 01/07/2026 (709 shares), 01/08/2026 (1,053 shares), and 02/04/2026 (640 shares). The excerpt lists 215,551,896 shares outstanding as of 02/24/2026.